Hope Medicine Initiates Phase III Trial for First-in-Class Non-Hormonal Endometriosis Treatment
核心洞察
Hope Medicine (搜索) has dosed the first patient in a Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting moderate-to-severe endometriosis (搜索) pain.
HMI-115 represents the first and only non-hormonal therapy globally to reach Phase III development for endometriosis (搜索) treatment.
The drug previously received Fast Track Designation from the FDA and Breakthrough Therapy Designation from China's NMPA based on positive Phase II results published in The Lancet.
Hope Medicine (搜索) Inc. has achieved a significant clinical milestone with the first patient dosing in its Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody designed to treat moderate-to-severe pain associated with endometriosis (搜索). The dosing took place at Peking Union Medical College Hospital in China, marking the beginning of the final development stage for what is currently the first and only non-hormonal therapy globally to enter Phase III clinical development for endometriosis.
Trial Design and Regulatory Recognition
The Phase III study is designed as a multicenter, randomized, double-blind, placebo-controlled trial with a 24-week treatment period. The trial aims to confirm the safety and efficacy of HMI-115 in treating moderate-to-severe pain associated with endometriosis (搜索), building on promising results from earlier development phases.
HMI-115 has garnered significant regulatory attention, receiving Fast Track Designation from the U.S. Food and Drug Administration (FDA) and Breakthrough Therapy Designation from China's National Medical Products Administration (NMPA). These designations were primarily based on results from a previously completed global multicenter Phase II clinical trial, which demonstrated that HMI-115 achieved statistically significant improvement in moderate-to-severe pain associated with endometriosis (搜索), with no significant impact on key female hormones and no menopausal side effects.
Clinical Evidence and Publication
The Phase II trial results have been published in The Lancet Obstetrics, Gynaecology, & Women's Health, providing peer-reviewed validation of the drug's therapeutic potential. The findings highlight HMI-115's unique profile as a non-hormonal treatment option, addressing a critical gap in current endometriosis (搜索) management approaches.
Disease Burden and Market Opportunity
Endometriosis (搜索) represents a substantial global health challenge, characterized by the implantation of endometrial cells outside the uterine cavity and typically presenting as a chronic inflammatory response. The condition affects approximately 10% of women of reproductive age globally, translating to about 190 million women worldwide.
The disease burden extends beyond prevalence statistics, with 20%-50% of women with infertility (搜索) having endometriosis (搜索), and 71%-87% of women with chronic pelvic pain (搜索) being affected by the condition. Endometriosis is recognized as one of the leading causes of dysmenorrhea (搜索), infertility, and chronic pelvic pain, significantly impacting patients' quality of life, sexual health, psychological well-being, and social behavior.
According to a McKinsey report cited by Hope Medicine (搜索), the global market represents a potential size of approximately US$200 billion, highlighting significant unmet medical needs in this therapeutic area.
Leadership Perspectives
Professor Xiao Ruiping, Founder of Hope Medicine (搜索), emphasized the significance of this milestone: "The initiation of the Phase III clinical trial for HMI-115 in endometriosis (搜索), marks a milestone achievement in our clinical development. Peking Union Medical College Hospital, as the leading site, is at the forefront of this Phase III study. Hope Medicine remains unwavering in its original commitment to bringing truly differentiated first-in-class medicines to patients worldwide."
Chen Xi, Chief Executive Officer of Hope Medicine (搜索), added: "The launch of the Phase III trial signifies that the global development of HMI-115 for endometriosis (搜索) has entered its final stage. Women's health is a key focus area for Hope Medicine, and we will drive this trial with the best speed and quality to bring this innovative treatment to patients as soon as possible."
Company Recognition
Hope Medicine (搜索)'s innovative approach has earned external recognition, with the company being nominated as "Best Startup" for the prestigious Prix Galien Award, further validating its scientific and commercial potential in addressing unmet medical needs in women's health.